Cargando…

Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience

Ewing sarcoma (ES) is a rare and aggressive disease that requires multidisciplinary treatment with the use of chemotherapy, radiotherapy, and surgery. Our retrospective study aimed to analyze the prognostic factors and treatment results in different age groups of patients. Between 1998 and 2018, 569...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagodzińska-Mucha, Paulina, Raciborska, Anna, Koseła-Paterczyk, Hanna, Kozak, Katarzyna, Bilska, Katarzyna, Świtaj, Tomasz, Falkowski, Sławomir, Dawidowska, Anna, Rutkowski, Piotr, Ługowska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397138/
https://www.ncbi.nlm.nih.gov/pubmed/34441922
http://dx.doi.org/10.3390/jcm10163627
_version_ 1783744547251027968
author Jagodzińska-Mucha, Paulina
Raciborska, Anna
Koseła-Paterczyk, Hanna
Kozak, Katarzyna
Bilska, Katarzyna
Świtaj, Tomasz
Falkowski, Sławomir
Dawidowska, Anna
Rutkowski, Piotr
Ługowska, Iwona
author_facet Jagodzińska-Mucha, Paulina
Raciborska, Anna
Koseła-Paterczyk, Hanna
Kozak, Katarzyna
Bilska, Katarzyna
Świtaj, Tomasz
Falkowski, Sławomir
Dawidowska, Anna
Rutkowski, Piotr
Ługowska, Iwona
author_sort Jagodzińska-Mucha, Paulina
collection PubMed
description Ewing sarcoma (ES) is a rare and aggressive disease that requires multidisciplinary treatment with the use of chemotherapy, radiotherapy, and surgery. Our retrospective study aimed to analyze the prognostic factors and treatment results in different age groups of patients. Between 1998 and 2018, 569 patients with ES were treated in two referral centers. The patients were divided into four age groups (≤10 years; 11–18 years; 19–25, and >25). The treatment results and prognostic factors were assessed for each group. For statistical analyses, we used the Chi2 test, the Kaplan–Meier estimator with a log-rank test, and the multivariate Cox model. Five-year overall survival (OS) rate was 56%. In the age subgroups: ≤10 years, 11–18 years, 19–25 years, and >25 years, the 5-year OS rates were 75%, 58%, 41%, and 52%, respectively. Favorable prognostic factors: female gender (p = 0.024), non-axial localization (p = 0.005), VIDE regimen (p < 0.001), and surgery as a local treatment (p < 0.001) dominated in the group ≤10 years. In multivariate analysis, male (HR = 1.53), axial localization (HR = 1.46), M1 status at presentation (HR = 2.64), and age > 10 years (HR = 2.29) were associated with shorter OS. The treatment results in ES are significantly better in children aged ≤10 years; the challenge is to provide therapy for adolescents and young adults. The diagnostics and treatment of ES patients must be provided in referral centers.
format Online
Article
Text
id pubmed-8397138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83971382021-08-28 Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience Jagodzińska-Mucha, Paulina Raciborska, Anna Koseła-Paterczyk, Hanna Kozak, Katarzyna Bilska, Katarzyna Świtaj, Tomasz Falkowski, Sławomir Dawidowska, Anna Rutkowski, Piotr Ługowska, Iwona J Clin Med Article Ewing sarcoma (ES) is a rare and aggressive disease that requires multidisciplinary treatment with the use of chemotherapy, radiotherapy, and surgery. Our retrospective study aimed to analyze the prognostic factors and treatment results in different age groups of patients. Between 1998 and 2018, 569 patients with ES were treated in two referral centers. The patients were divided into four age groups (≤10 years; 11–18 years; 19–25, and >25). The treatment results and prognostic factors were assessed for each group. For statistical analyses, we used the Chi2 test, the Kaplan–Meier estimator with a log-rank test, and the multivariate Cox model. Five-year overall survival (OS) rate was 56%. In the age subgroups: ≤10 years, 11–18 years, 19–25 years, and >25 years, the 5-year OS rates were 75%, 58%, 41%, and 52%, respectively. Favorable prognostic factors: female gender (p = 0.024), non-axial localization (p = 0.005), VIDE regimen (p < 0.001), and surgery as a local treatment (p < 0.001) dominated in the group ≤10 years. In multivariate analysis, male (HR = 1.53), axial localization (HR = 1.46), M1 status at presentation (HR = 2.64), and age > 10 years (HR = 2.29) were associated with shorter OS. The treatment results in ES are significantly better in children aged ≤10 years; the challenge is to provide therapy for adolescents and young adults. The diagnostics and treatment of ES patients must be provided in referral centers. MDPI 2021-08-17 /pmc/articles/PMC8397138/ /pubmed/34441922 http://dx.doi.org/10.3390/jcm10163627 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jagodzińska-Mucha, Paulina
Raciborska, Anna
Koseła-Paterczyk, Hanna
Kozak, Katarzyna
Bilska, Katarzyna
Świtaj, Tomasz
Falkowski, Sławomir
Dawidowska, Anna
Rutkowski, Piotr
Ługowska, Iwona
Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
title Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
title_full Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
title_fullStr Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
title_full_unstemmed Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
title_short Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
title_sort age as a prognostic factor in patients with ewing sarcoma—the polish sarcoma group experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397138/
https://www.ncbi.nlm.nih.gov/pubmed/34441922
http://dx.doi.org/10.3390/jcm10163627
work_keys_str_mv AT jagodzinskamuchapaulina ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT raciborskaanna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT kosełapaterczykhanna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT kozakkatarzyna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT bilskakatarzyna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT switajtomasz ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT falkowskisławomir ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT dawidowskaanna ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT rutkowskipiotr ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience
AT ługowskaiwona ageasaprognosticfactorinpatientswithewingsarcomathepolishsarcomagroupexperience